Skip to Content

Gadobutrol Dosage

Applies to the following strength(s): 604.72 mg/mL

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for CNS Magnetic Resonance Imaging

0.1 mL/kg body weight (0.1 mmol/kg) IV bolus injection
Comments: Administer manually or by power injector at a flow rate of approximately 2 mL/second. Refer to manufacturer product information to determine volume to be administered.

Use: Indicated for use with MRI to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system.

Usual Adult Dose for Diagnostic

0.1 mL/kg body weight (0.1 mmol/kg) IV bolus injection
Comments: Administer manually or by power injector at a flow rate of approximately 2 mL/second. Refer to manufacturer product information to determine volume to be administered.

Use: Indicated for use with MRI to assess the presence and extent of malignant breast disease.

Usual Pediatric Dose for CNS Magnetic Resonance Imaging

0.1 mL/kg body weight (0.1 mmol/kg) IV bolus injection
Comments: Administer manually or by power injector at a flow rate of approximately 2 mL/second. Refer to manufacturer product information to determine volume to be administered.

Use:
-Indicated for use with MRI to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system.

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

Data not available

Precautions

BOXED WARNING:
-NEPHROGENIC SYSTEMIC FIBROSIS (NSF)
-Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs.
-Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities.
-The risk for NSF appears highest among patients with: chronic, severe kidney disease (GFR less than 30 mL/min/1.73 m2), or acute kidney injury.
-Screen patients for acute kidney injury and other conditions that may reduce renal function.
-For patients at risk for chronically reduced renal function (e.g., age greater than 60 years, hypertension or diabetes), estimate the GFR through laboratory testing
-NSF may result in fatal or debilitating fibrosis affecting the skin, muscle, and internal organs.
-For patients at highest risk of NSF, do not exceed recommended dose and allow for a sufficient period of time for elimination of the drug prior to re-administration.

Consult WARNINGS section for additional precautions.

Dialysis

Hemodialysis: May consider the prompt initiation of hemodialysis following the administration of the drug in order to enhance elimination.
Peritoneal dialysis: Data not available

Other Comments

Administration advice:
-Administer as IV bolus injection (manually or power injector) at a flow rate of approximately 2 mL/second.
-Follow injection with saline flush to ensure complete administration of the drug.
-Contrast enhanced MRI can begin immediately following drug administration.

Storage requirements:
-Store at 25C (77F); excursions permitted to 15 to 30C (59 to 86F).
-If freezing of drug occurs, bring to room temperature before use.
-If allowed to stand at room temperature, the drug should return to a clear and colorless to pale yellow solution.

Reconstitution/preparation techniques: Refer to manufacturer product information

IV compatibility: Do not mix or co-infuse with other IV medications.

General: False positive detection rates for breasts with malignancy ranged from 39% to 53%.

Monitoring:
-Screen patients for acute kidney injury (AKI) and other conditions that may reduce renal function. Estimate GFR for patients who are at risk for chronically reduced renal function (age greater than 60, diabetes, or hypertension).
-Monitor patients closely during and after administration of the drug for signs and symptoms of hypersensitivity reactions.

Patient advice:
-Instruct the patients to contact their physician if they develop signs or symptoms of NSF following administration of the drug, such as burning, itching, swelling, scaling, hardening and tightening of the skin; red or dark patches on the skin; stiffness in joints with trouble moving, bending or straightening the arms, hands, legs or feet; pain in the hip bones or ribs; or muscle weakness.

Hide